Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

被引：13
|
作者：
Gilabert, Marine [1 ,2 ]
Raoul, Jean-Luc [3 ]
机构：
[1] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguerite, F-13232 Marseille 9, France
[2] Aix Marseille Univ, Inst Natl Sante & Rech Med 1068, Stress Cell Unit, Ctr Rech Cancerol Marseille, Marseille 8, France
[3] Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, F-44805 Nantes, France
来源：
JOURNAL OF HEPATOCELLULAR CARCINOMA | 2018年 / 5卷
关键词：
hepatocellular carcinoma; antiangiogenic drugs; ramucirumab; RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; OPEN-LABEL; SORAFENIB; PLACEBO; CHEMOTHERAPY; MULTICENTER; COMBINATION; THERAPY;
D O I：
10.2147/JHC.S157413
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Hepatocellular carcinoma (HCC) represents similar to 90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first-and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.
引用
收藏
页码：91 / 98
页数：8
相关论文
共 50 条
  • [31] Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis
    Llovet, J.
    Kudo, M.
    Kang, Y-K.
    Yen, C-J.
    Finn, R. S.
    Galle, P. R.
    Assenat, E.
    Motomura, K.
    Okusaka, T.
    Berg, T.
    Hsu, C-H.
    Ikeda, M.
    Hsu, Y.
    Liang, K.
    Widau, R.
    Schelman, W.
    O'Brien, L.
    Gao, L.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2019, 30 : 293 - +
  • [32] Hepatocellular carcinoma: Patients with increasing alpha-fetoprotein but no mass on ultrasound
    Llovet, JM
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (01) : 29 - 35
  • [33] Impact of elevated alpha-fetoprotein level on the survival outcome of unresectable hepatocellular carcinoma
    Almezaine, A. S. E.
    Ellaithy, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S90 - S90
  • [34] Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
    Zhu, Andrew X.
    Nipp, Ryan D.
    Finn, Richard S.
    Galle, Peter R.
    Llovet, Josep M.
    Blanc, Jean-Frederic
    Okusaka, Takuji
    Chau, Ian
    Cella, David
    Girvan, Allicia
    Gable, Jonathon
    Bowman, Lee
    Wang, Chunxiao
    Hsu, Yanzhi
    Abada, Paolo B.
    Kudo, Masatoshi
    ESMO OPEN, 2020, 5 (04)
  • [35] The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma
    Tomokuni, Akira
    Kobayashi, Shogo
    Wada, Hiroshi
    Asukai, Kei
    Yamada, Daisaku
    Akita, Hirofumi
    Takahashi, Hidenori
    Omori, Takeshi
    Yasui, Masayoshi
    Miyata, Hiroshi
    Ohue, Masayuki
    Yano, Masahiko
    Sakon, Masato
    CANCER SCIENCE, 2018, 109 : 939 - 939
  • [36] Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients
    Wu, Guoyi
    Wu, Jing
    Pan, Xiaoben
    Liu, Bo
    Yao, Zhicheng
    Guo, Yuan
    Shi, Xiaolei
    Ding, Yitao
    CANCER MEDICINE, 2019, 8 (15): : 6614 - 6623
  • [37] Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma
    Soresi, M
    Magliarisi, C
    Campagna, P
    Leto, G
    Bonfissuto, G
    Riili, A
    Carroccio, A
    Sesti, R
    Tripi, S
    Montalto, G
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1747 - 1753
  • [38] EXCESSIVE ALPHA-FETOPROTEIN CONCENTRATIONS IN HEPATOCELLULAR CARCINOMA
    AMERY, AH
    ALSTON, WC
    KOHN, J
    WHITE, WF
    BRITISH MEDICAL JOURNAL, 1977, 2 (6087): : 611 - 612
  • [39] Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
    Galle, Peter R.
    Foerster, Friedrich
    Kudo, Masatoshi
    Chan, Stephen L.
    Llovet, Josep M.
    Qin, Shukui
    Schelman, William R.
    Chintharlapalli, Sudhakar
    Abada, Paolo B.
    Sherman, Morris
    Zhu, Andrew X.
    LIVER INTERNATIONAL, 2019, 39 (12) : 2214 - 2229
  • [40] QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN
    Gable, J.
    Ayer, D.
    Girvan, A.
    Bowman, L.
    Abada, P.
    Ervin, C.
    Evans, E.
    Cella, D.
    VALUE IN HEALTH, 2018, 21 : S76 - S76
12345